Skip to main content

Medical Management of Ulcerative Colitis

  • Chapter
  • First Online:
Contemporary Coloproctology
  • 997 Accesses

Abstract

Ulcerative colitis (UC) affects about 1 in 400 of the UK population, with a stable incidence in the last few decades. The peak age of onset of disease is around 30 years, but onset of disease can occur at any age, though it is rare after 70 years [1]. The strongest risk factor for developing UC is a family history of inflammatory bowel disease (IBD) (either UC or Crohn’s disease); however, the risk of monozygotic twins developing UC is lower than for Crohn’s disease (10% versus 38%) broadly suggesting that UC is less “genetic” than CD [1].

In Memoriam: Keith Leiper 1967–2011

Dr. Keith Leiper, universally loved by his patients and by all the staff with whom he worked, all of whom he treated as his friends, died from cancer on Friday, October 21, 2011. Keith had been the Leslie Parrott Research Fellow of Crohn’s and Colitis UK and completed his M.D. on the pathogenesis and treatment of inflammatory bowel disease before going on to be a consultant with a passionate interest in clinical research. On a national level, his outstanding work as the first lead for the UK Inflammatory Bowel Disease Audit has led to a marked improvement in standards of IBD care, an achievement brought about through his close collaboration with patient organizations, particularly Crohn’s and Colitis UK for whom Keith acted as a regional medical advisor. But far more than his (formidable) list of achievements can attest, Keith was an inspiration to all who met him: exceptionally widely read, possessing a phenomenal grasp of the medical literature, an enthusiastic and much loved teacher and trainer, and immensely beneficial to the care of IBD patients locally; his personality, enormous kindness, selfless generosity, integrity, and constant good humor will be particularly remembered. He was unfailingly fun to be with, even when he became ill, and was constantly prioritizing others above himself. He is survived by his wife Libby, also a doctor, and by their children Cameron, Mirren, and Ailish to whom our thoughts go.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stange EF, Travis SPL, Vermeire S. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.

    Article  PubMed  Google Scholar 

  2. Moser G. How often do patients with IBD have symptom recurrence? Inflamm Bowel Dis. 2008;14 Suppl 2:S47. Erratum in: Inflamm Bowel Dis. 2009;15:1438–47.

    Article  PubMed  Google Scholar 

  3. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.

    Article  PubMed  CAS  Google Scholar 

  4. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000;46 Suppl 1:i1–8.

    Article  PubMed  Google Scholar 

  5. Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci. 2010;55:2002–7.

    Article  PubMed  CAS  Google Scholar 

  6. Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–37.

    Article  PubMed  CAS  Google Scholar 

  7. Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut. 2009;58:1313–5.

    Article  PubMed  Google Scholar 

  8. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.

    Article  PubMed  CAS  Google Scholar 

  9. Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009;30:614–20.

    Article  PubMed  CAS  Google Scholar 

  10. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(3):CD005112

    Google Scholar 

  11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005;353:2462–76.

    Google Scholar 

  12. Ulcerative colitis (subacute manifestations)- infliximab. 2010. www.nice.org.uk/nicemedia/pdf/TA140Guidance

  13. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.

    Article  PubMed  Google Scholar 

  14. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.

    Article  PubMed  CAS  Google Scholar 

  15. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–50.

    Article  PubMed  Google Scholar 

  16. Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2010;32:615–27.

    PubMed  CAS  Google Scholar 

  17. Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820–9.

    Article  PubMed  CAS  Google Scholar 

  18. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keith Leiper .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag London Limited

About this chapter

Cite this chapter

Flanagan, P., Leiper, K. (2012). Medical Management of Ulcerative Colitis. In: Brown, S., Hartley, J., Hill, J., Scott, N., Williams, J. (eds) Contemporary Coloproctology. Springer, London. https://doi.org/10.1007/978-0-85729-889-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-889-8_17

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-888-1

  • Online ISBN: 978-0-85729-889-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics